Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 91 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2014', provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 9
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Comparative Analysis 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies 16
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 17
Anthera Pharmaceuticals� Inc. 17
Azano Pharmaceuticals Inc. 18
Boehringer Ingelheim GmbH 19
Eisai Co., Ltd. 20
GlaxoSmithKline plc 21
HanAll Biopharma Co., Ltd. 22
Immunomedics, Inc. 23
Merck & Co., Inc. 24
Momenta Pharmaceuticals, Inc. 25
Pfizer Inc. 26
PhytoHealth Corporation 27
Rigel Pharmaceuticals, Inc. 28
SuppreMol GmbH 29
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
avatrombopag - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AZ-175 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
belimumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BI-655064 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
blisibimod - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
eltrombopag olamine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fostamatinib disodium - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GL-2045 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GSK-2285921 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HL-161 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MK-8723 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PHN-013 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SM-101 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
veltuzumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Recent Pipeline Updates 67
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects 81
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products 82
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones 83
Featured News & Press Releases 83
Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 83
Dec 09, 2013: Immunomedics Reports Promising Activity With Veltuzumab In Relapsed Immune Thrombocytopenia 83
Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 84
Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance 84
Jun 12, 2013: GSK's Revolade Receives Positive Recommendation From NICE For Treatment Of Idiopathic Thrombocytopenic Purpura 85
Mar 20, 2013: GSK's Eltrombopag Receives NICE Recommendation For Treatment Of Chronic Immune Thrombocytopenic Purpura 85
Dec 18, 2012: NICE Recommends GlaxoSmithKline's Eltrombopag For Treatment Of Chronic Immune Thrombocytopenic Purpura 86
Dec 11, 2012: Immunomedics Provides Clinical Updates On Subcutaneous Injections Of Veltuzumab In Autoimmune Disease And Cancer 87
Dec 10, 2012: SuppreMol's SM101 Shows Sustained Clinical Activity And Favorable Safety Profile In Primary Immune Thrombocytopenia Patients 88
Nov 07, 2012: SuppreMol Announces Presentation Of Clinical Data For SM101 At 54th ASH Annual Meeting 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 91
Disclaimer 91

List of Tables
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2014 9
Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Anthera Pharmaceuticals� Inc., H2 2014 17
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Azano Pharmaceuticals Inc., H2 2014 18
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 19
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Eisai Co., Ltd., H2 2014 20
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by GlaxoSmithKline plc, H2 2014 21
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 22
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H2 2014 23
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H2 2014 24
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014 25
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H2 2014 26
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H2 2014 27
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2014 28
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by SuppreMol GmbH, H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics - Recent Pipeline Updates, H2 2014 67
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2014 81
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2014 82